QC
UTHR icon

Quantedge Capital’s United Therapeutics UTHR Stock Holding History

Quantedge Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,500
Closed -$882K – 148
2024
Q4 		$882K Hold
2,500
– – 0.32% 76
2024
Q3 		$896K Buy
+2,500
New +$844K 0.27% 90
2021
Q4 		– Sell
-2,200
Closed -$406K – 241
2021
Q3 		$406K Hold
2,200
– – 0.2% 118
2021
Q2 		$395K Buy
+2,200
New +$419K 0.33% 85

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Quantedge Capital's UTHR Position: Q1 2025 in Review

Quantedge Capital sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 2,500 shares — an estimated $882K sold.

Quantedge Capital first reported a position in UTHR in Q2 2021 and held it in 4 quarters. The position peaked at $896K in Q3 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • Quantedge Capital reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Quantedge Capital sold 2,500 United Therapeutics shares in Q1 2025, an estimated $882K.
  • Quantedge Capital first reported a position in United Therapeutics in Q2 2021 and held it in 4 quarters.
  • Quantedge Capital's United Therapeutics position peaked at $896K in Q3 2024.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Quantedge Capital's 13F filing for Q1 2025, filed 15 May 2025.